GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Price-to-Owner-Earnings

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Price-to-Owner-Earnings?

As of today (2024-04-29), Scinai Immunotherapeutics's share price is $0.44. Scinai Immunotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Scinai Immunotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 12 years, the highest Price-to-Owner-Earnings of Scinai Immunotherapeutics was 16.71. The lowest was 0.00. And the median was 0.00.


SCNI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), Scinai Immunotherapeutics's share price is $0.44. Scinai Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.20. Therefore, Scinai Immunotherapeutics's PE Ratio for today is At Loss.

As of today (2024-04-29), Scinai Immunotherapeutics's share price is $0.44. Scinai Immunotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-5.20. Therefore, Scinai Immunotherapeutics's PE Ratio without NRI for today is At Loss.


Scinai Immunotherapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Scinai Immunotherapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Price-to-Owner-Earnings Chart

Scinai Immunotherapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scinai Immunotherapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Scinai Immunotherapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Scinai Immunotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Price-to-Owner-Earnings falls into.



Scinai Immunotherapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Scinai Immunotherapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.44/-2.06
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinai Immunotherapeutics  (NAS:SCNI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Scinai Immunotherapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Headlines